Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases

Overview

Journal Nutrients

Date 2019 Feb 6

PMID 30717085

Citations 7

Authors

Rocco Spagnuolo

Tiziana Montalcini

Daniele De Bonis

Yvelise Ferro

Cristina Cosco

Elisa Mazza

Stefano Romeo

Patrizia Doldo

Arturo Pujia

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Most studies focused on the benefits of weight loss on hepatic steatosis and no studies have been specifically designed to assess the role of weight gain on the development of liver steatosis in patients affected by inflammatory bowel diseases. The aim of this study was to analyse the relation between weight change over time and liver steatosis in patients with inflammatory bowel diseases.

Methods: We retrospectively evaluated a population of 89 ambulatory patients in clinical remission or affected by mild disease, as determined from disease activity indices, with at least one follow-up visit. Transient elastography was used to quantify liver steatosis.

Results: A total of 49 individuals (55%) were overweight/obese at baseline. A significant difference in weight change was found between participants that improved, were stable and worsened, over a mean follow-up of four years. (-1.0 kg ± 4; 2.5 kg ± 6; and 5.4 kg ± 5; respectively, = 0.009). We found a greater probability of worsening in the hepatic fat content in individuals who gained more than 6% of body weight than in those gaining less than this value (log⁻rank (Mantel⁻Cox) χ² test = 9.85; df = 1; = 0.002).

Conclusions: A body weight gain of 6% increases the probability of deterioration in liver steatosis over a period of four years in patients with inflammatory bowel diseases. Weight gain prevention with lifestyle interventions may be the cornerstone treatment of these patients.

Citing Articles

Wet pulverization combined with temperature cycling strategy for extraction of protein with attenuating hepatic steatosis on obese mice.

Liu P, Gao C, Li W, Chen W, Zhang Z, Wu D Food Chem X. 2025; 25:102170.

PMID: 39897974 PMC: 11782863. DOI: 10.1016/j.fochx.2025.102170.

Protocol of quantitative ultrasound techniques for noninvasive assessing of hepatic steatosis after bariatric surgery.

Chen B, Lu Q, Hu B, Sun D, Ying T Front Surg. 2024; 10:1244199.

PMID: 38239667 PMC: 10794322. DOI: 10.3389/fsurg.2023.1244199.

Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study.

Abenavoli L, Spagnuolo R, Scarlata G, Scarpellini E, Boccuto L, Luzza F Medicina (Kaunas). 2023; 59(11).

PMID: 38003983 PMC: 10673463. DOI: 10.3390/medicina59111935.

Effects of 12 Weeks of Family and Individual Multi-Disciplinary Intervention in Overweight and Obese Adolescents under Cardiometabolic Risk Parameters: A Clinical Trial.

Marques D, Dos Santos Moraes L, Marques M, Ryal J, Santos I, Lalucci M Int J Environ Res Public Health. 2023; 20(20).

PMID: 37887692 PMC: 10606176. DOI: 10.3390/ijerph20206954.

Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review.

Martinez-Dominguez S, Garcia-Mateo S, Laredo V, Gargallo-Puyuelo C, Gallego Llera B, Lopez de la Cruz J Cancers (Basel). 2023; 15(13).

PMID: 37444477 PMC: 10340150. DOI: 10.3390/cancers15133367.

References

Bellentani S, Saccoccio G, Masutti F, Croce L, Brandi G, Sasso F . Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000; 132(2):112-7. DOI: 10.7326/0003-4819-132-2-200001180-00004. View

Unger R, Orci L . Lipotoxic diseases of nonadipose tissues in obesity. Int J Obes Relat Metab Disord. 2000; 24 Suppl 4:S28-32. DOI: 10.1038/sj.ijo.0801498. View

Unger R, Zhou Y . Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes. 2001; 50 Suppl 1:S118-21. DOI: 10.2337/diabetes.50.2007.s118. View

Unger R . The physiology of cellular liporegulation. Annu Rev Physiol. 2002; 65:333-47. DOI: 10.1146/annurev.physiol.65.092101.142622. View

Stranges S, Dorn J, Muti P, Freudenheim J, Farinaro E, Russell M . Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology. 2004; 39(3):754-63. DOI: 10.1002/hep.20149. View

Ueki K, Kondo T, Tseng Y, Kahn C . Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A. 2004; 101(28):10422-7. PMC: 478587. DOI: 10.1073/pnas.0402511101. View

Daperno M, DHaens G, Van Assche G, Baert F, Bulois P, Maunoury V . Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004; 60(4):505-12. DOI: 10.1016/s0016-5107(04)01878-4. View

Cai D, Yuan M, Frantz D, Melendez P, Hansen L, Lee J . Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005; 11(2):183-90. PMC: 1440292. DOI: 10.1038/nm1166. View

Unger R . Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. Biochimie. 2005; 87(1):57-64. DOI: 10.1016/j.biochi.2004.11.014. View

10.

Montalcini T, Gorgone G, Federico D, Ceravolo R, Emanuele V, Sesti G . Association of LDL cholesterol with carotid atherosclerosis in menopausal women affected by the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2005; 15(5):368-72. DOI: 10.1016/j.numecd.2004.10.003. View

11.

Morino K, Petersen K, Shulman G . Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes. 2006; 55 Suppl 2:S9-S15. PMC: 2995546. DOI: 10.2337/db06-S002. View

12.

. Use of cessation methods among smokers aged 16-24 years--United States, 2003. MMWR Morb Mortal Wkly Rep. 2006; 55(50):1351-4. View

13.

DHaens G, Sandborn W, Feagan B, Geboes K, Hanauer S, Irvine E . A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132(2):763-86. DOI: 10.1053/j.gastro.2006.12.038. View

14.

Nguyen G, Munsell M, Harris M . Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflamm Bowel Dis. 2008; 14(8):1105-11. DOI: 10.1002/ibd.20429. View

15.

Promrat K, Kleiner D, Niemeier H, Jackvony E, Kearns M, Wands J . Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2009; 51(1):121-9. PMC: 2799538. DOI: 10.1002/hep.23276. View

16.

Lazo M, Solga S, Horska A, Bonekamp S, Diehl A, Brancati F . Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010; 33(10):2156-63. PMC: 2945152. DOI: 10.2337/dc10-0856. View

17.

de Ledinghen V, Wong V, Vergniol J, Wong G, Foucher J, Chu S . Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. J Hepatol. 2011; 56(4):833-9. DOI: 10.1016/j.jhep.2011.10.017. View

18.

Myers R, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M . Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012; 32(6):902-10. DOI: 10.1111/j.1478-3231.2012.02781.x. View

19.

de Ledinghen V, Vergniol J, Foucher J, Merrouche W, Le Bail B . Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012; 32(6):911-8. DOI: 10.1111/j.1478-3231.2012.02820.x. View

20.

Nic Suibhne T, Raftery T, McMahon O, Walsh C, OMorain C, OSullivan M . High prevalence of overweight and obesity in adults with Crohn's disease: associations with disease and lifestyle factors. J Crohns Colitis. 2012; 7(7):e241-8. DOI: 10.1016/j.crohns.2012.09.009. View